针对CGRP和5-HT1F受体的偏头痛急性期治疗药物研究进展

摘要/Abstract

摘要： 目前偏头痛的急性期治疗包括非特异性止痛和曲坦类药物治疗。这些药物的局限性包括：在许多患者中缺乏疗效、不良反应多、曲坦类药物在心血管疾病患者中的禁忌证等,这些都表明对偏头痛新疗法的需求尚未得到满足。对5-羟色胺（5-HT）药理学的研究促进了曲坦类药物（5-HT_1B/1D受体激动剂）的发展,其中一些是在5-HT_1F受体上起作用。对降钙素基因相关肽（CGRP）作用的探索引起了CGRP受体拮抗剂的发展。本文就近几年针对CGRP和5-HT_1F受体的偏头痛急性治疗的主要进展综述如下。

关键词: 偏头痛, CGRP, 5-HT_1F, 急性期治疗, 研究进展

Abstract: Present,the acute treatment of migraine includes non-specific pain relief and triptan drugs.The limitations of these drugs include: lack of efficacy in many patients, many side effects, contraindications of triptan drugs in patients with cardiovascular disease, and so on, which indicate that the demand for new treatments for migraine has not been met. The pharmacological study of 5-hydroxytryptamine (5-HT) has promoted the development of triptan drugs (5-HT_1B/1Dreceptor agonists), some of which act on 5-HT_1F receptors. The exploration of the role of calcitonin gene-related peptide (CGRP) has led to the development of CGRP receptor antagonists. This article reviews the main progress in the acute treatment of migraine with CGRP and 5-HT_1F receptors in recent years.

Key words: migraine, CGRP, 5-HT_1F, acute phase treatment, research progress

中图分类号:

R747.2

陈娅茹, 宰风雷. 针对CGRP和5-HT_1F受体的偏头痛急性期治疗药物研究进展[J]. 中华养生保健, 2022, 40(21): 64-67.

CHEN Ya-ru, ZAI Feng-lei. Research Progress of Drugs for Acute Migraine Targeting CGRP and 5-HT_1FReceptors[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(21): 64-67.

参考文献

[1] Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders,3rd edition[J]. Cephalalgia,2018,38(1):1-211.
[2] Steiner T J, Stovner L J, Vos T, et al.Migraine is first cause of disability in under 50s: will health politicians now take notice?[J]. Headache Pain,2018,19(1):17.
[3] Paolo Martelletti, Todd J.Schwedt, Michel Lanteri-Minet, et al. My Migraine Voice survey: a global study of disease burden among individuals with migrainefor whom preventive treatments have failed[J]. Headache Pain, 2018,19(1):115.
[4] Andrea Negro, Valerio Spuntarelli, Sciattella P, et al.Rapid referral for headache management from emergency department to headache centre: four years data[J]. Headache Pain, 2020,21(1):25.
[5] M D Ferrari, Goadsby P J, Lipton R B, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials[J]. Cephalalgia, 2002,22(8):633-658.
[6] T J Steiner, R Jensen, Z Katsarava, et al.Aids to management of headache disorders in primary care (2nd edition) on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache[J]. Headache Pain, 2019,20(1):57.
[7] Fabio Antonaci, Natascia Ghiotto, Shizheng Wu, et al.Recent advances in migraine therapy[J]. Springerplus, 2016,(5):637.
[8] Gilles Géraud M, Charlotte Keywood M, Jean Michel Senard M. Migraine Headache Recurrence: Relationship to Clinical, Pharmacological, and Pharmacokinetic Properties of Triptans[J]. Headache, 2003,43(4):376-388.
[9] Luana Lionetto M B M C, Fabiola Cipolla, Gentile G, et al. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations[J]. Expert Opin Drug Metab Toxicol, 2016,12(4):399-406.
[10] K Thorlund, K Toor, P Wu, et al.Comparative tolerability of treatments for acute migraine: A network meta-analysis[J]. Cephalalgia, 2017,37(10):965-978.
[11] 董钊,林晓雪,刘颖元,等.偏头痛急性期和预防性治疗进展[J].中国现代神经疾病杂志,2022,22(2):99-103.
[12] Eloísa Rubio-Beltrán A, Alejandro Labastida-Ramírez A, Carlos M. Villalón B, et al. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?[J]. Pharmacol Ther, 2018,186:88-97.
[13] Lee S, Staatz C E, Han N, et al.Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis.[J]. European journal of clinical pharmacology, 2022,78:1365-1376.
[14] Blakely K K, Stallworth K.Lasmiditan Is a New Option for Acute Migraine Treatment.[J]. Nursing for women's health, 2020,24(4):294-299.
[15] Antoinette MaassenVanDenBrink J M, Carlos M. Villalón, Ferrari M D. Wiping Out CGRP: Potential Cardiovascular Risks[J]. Trends Pharmacol, 2016,37(9):779-788.
[16] 郝雨雁,琍杨,肖哲曼.偏头痛发病相关机制的研究_郝雨雁[J].中风与神经疾病杂志,2022,39(3):267-270.
[17] P C Tfelt-Hansen. Does sumatriptan cross the blood-brain barrier in animals and man[J]. Headache Pain, 2010,11(1):5-12.
[18] Y Sakai, C Dobson, M Diksic, et al.Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis[J]. Neurology, 2008,70(6):431-439.
[19] A Negro, A Koverech, P Martelletti.Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential[J]. Pain Res, 2018,11:515-526.
[20] Lundblad C, Kristian A H, Gustaf G, et al.Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage[J]. Headache, 2015,16:91.
[21] D Pietrobon, M A Moskowitz.Pathophysiology of Migraine[J]. Ann Rev, 2013,75:365-391.
[22] Wainscott D B, Krushinski J H, Audia J E, et al.[3H]LY334370, a novel radioligand for the 5-HT1F receptor.I. In vitro characterization of binding properties[J]. Naunyn Schmiedebergs Arch, 2005,371(3):169-177.
[23] Brandes J L, Suzanne K, John H K, et al.Interim results of a prospective,randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)[J]. Cephalalgia, 2019,39(11):1343-1357.
[24] E T Haar, C M Koth, N Abdul-Manan, et al.Crystal Structure of the Ectodomain Complex of the CGRP Receptor, a Class-B GPCR, Reveals the Site of Drug Antagonism[J]. Structure, 2010,18(9):1083-1093.
[25] K Y Chan, L Edvinsson, S Eftekhari, et al.Characterization of the Calcitonin Gene-Related Peptide Receptor Antagonist Telcagepant (MK-0974) in Human Isolated Coronary Arteries[J]. Pharmacol Exp, 2010,334(3):746-752.
[26] K A Petersen K, S Birk, L H Lassen, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers[J]. Cephalalgia, 2005,25(2):139-147.
[27] J Olesen, H C Diener, I W Husstedt, et al.Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine[J]. N Engl J Med, 2004,350(11):1104-1110.
[28] K M Connor M, R Shapiro M P, H C Diener M, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine[J]. Neurology., 2009,73(12):970-977.
[29] Ho A P, Carl G D F, Stephen D S, et al. Randomized, controlled trial of telcagepant over four migraine attacks[J]. Cephalalgia,30(12):1443-1457.
[30] Hewitt D J, Sheena K A, David W D, et al.Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine[J]. Cephalalgia, 2011,31(6):712-722.
[31] Diener H, Piero B, Carl D F, et al.BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study.[J]. Cephalalgia, 2011,31(5):573-584.
[32] B R Lipton, R Croop, E G Stock, et al.Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine[J]. N Engl J Med., 2019,381(2):142-149.
[33] Voss T, Richard B L, Dupre N, et al.A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine[J]. Cephalalgia, 2016,36(9):887-898.
[34] Richard B, Lipton M, David W.et al.Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine The ACHIEVE II Randomized Clinical Trial[J]. JAMA, 2019,322(19):1887-1898.
[35] E Rubio-Beltrán, E Alejandro, A Labastida-Ramírez, et al.Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan[J]. Characterization of binding, functional activity, and contractile, 2019,176(24):4681-4695.
[36] Ferrari M D, Markus F R, Uwe R, et al.Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - A randomised proof-of-concept trial[J]. Cephalalgia, 2010,30(10):1170-1178.
[37] B Kuca, D Stephen, G Dozier, et al.COL MIG-301 Study Group Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study.[J]. Neurology, 2018,91(24):1894-1904.
[38] Peter J. Goadsby, Linda A. Wietecha, Ellen B.Dennehy, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.[J]. 2019,142(7):1894-1904.
[39] Yu T, He L, Yang X, et al.Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial[J]. Neurol Ther, 2022,17(6):1269-1283.
[40] B R Chaitman, A P Ho, M O Behm, et al.A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina.[J]. Clin Pharmacol Ther, 2012,91:459-466.
[41] Razzaque Z, M A Heald, J D Pickard. Vasoconstriction in human isolated middle meningeal arteries:Determining the contribution of 5-HT(1B)- and 5-HT(1F)-receptor activation[J]. Br J Clin Pharmacol, 1999,47:75-82.
[42] Marcus R, Peter J G, David D, et al.BMS-927711 for the acute treatment of migraine: A double-blind,randomized,placebo controlled, dose-ranging trial[J]. Cephalalgia, 2014,34:114-125.
[43] P J Goadsby, S J Tepper, P B Watkins, et al.Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized,placebo-controlled trial in healthy adults[J]. Cephalalgia, 2019,39(14):1753-1761.